Revance Therapeutics, Inc. - FORM 10-K - EX-21.1 - February 25, 2021

Attached files

file	filename
EX-32.2 - EX-32.2 - Revance Therapeutics, Inc.	ex_322xcertificationofpfox.htm
EX-32.1 - EX-32.1 - Revance Therapeutics, Inc.	ex_321xcertificationofpeox.htm
EX-31.2 - EX-31.2 - Revance Therapeutics, Inc.	ex_312xertificationofpfoxf.htm
EX-31.1 - EX-31.1 - Revance Therapeutics, Inc.	ex_311xcertificationofpeox.htm
EX-23.1 - EX-23.1 - Revance Therapeutics, Inc.	ex_231xpublicaccountingfir.htm
EX-10.35 - EX-10.35 - Revance Therapeutics, Inc.	ex1035_amendmenttofosunagr.htm
EX-10.31 - EX-10.31 - Revance Therapeutics, Inc.	ex1031_amendementabpsxfy20.htm
EX-10.27 - EX-10.27 - Revance Therapeutics, Inc.	ex1027_managementbonusplan.htm
EX-10.20 - EX-10.20 - Revance Therapeutics, Inc.	ex_1020xamendmenttonashvil.htm
EX-10.11 - EX-10.11 - Revance Therapeutics, Inc.	ex1011_rsax2014inxfy2010-k.htm
EX-10.6 - EX-10.6 - Revance Therapeutics, Inc.	ex106_rsax2014eipxfy2010-k.htm
EX-4.4 - EX-4.4 - Revance Therapeutics, Inc.	ex44_descriptionofcommonst.htm
10-K - 10-K - Revance Therapeutics, Inc.	rvnc-20201231.htm

Exhibit 21.1

REVANCE THERAPEUTICS, INC.

LIST OF SUBSIDIARIES

1.Revance Therapeutics Ltd., incorporated in England and Wales.

2.Revance International Limited, incorporated in the Cayman Islands.

3.Hint, Inc. (d/b/a HintMD), incorporated in Delaware.